TrialCancer discovery2023

MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.

Lars D Engstrom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.